论文部分内容阅读
β受体阻滞剂曾被誉为“200年以来继发现洋地黄后的最伟大发现”。目前,β受体阻滞剂广泛用于高血压、冠状动脉性心脏病(冠心病)、心力衰竭和心律失常的治疗。然而,自从英国国家卫生与临床优化研究所(the national institute for health and clinical excellence,NICE)指南从2006年颁布后,临床医生对β受体阻滞剂的关注却变成对其疗效及预后的质疑。笔者针对目前质疑的一些问题从药学的角度谈几点认识。
Beta-blockers have been hailed as “200 years since the discovery of digitalis after the greatest discovery ”. Currently, β-blockers are widely used in the treatment of hypertension, coronary heart disease (CHD), heart failure and arrhythmia. However, since the guidance of the National Institute for Health and Clinical Excellence (NICE) was promulgated in 2006, clinicians have turned their attention to beta-blockers to their efficacy and prognosis question. The author asked some questions about the current question from a pharmacy point of understanding.